1. Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate
- Author
-
Shan Mei, Zhangling Fan, Xiaoman Liu, Fei Zhao, Yu Huang, Liang Wei, Yamei Hu, Yu Xie, Liming Wang, Bin Ai, Chen Liang, Fengwen Xu, and Fei Guo
- Subjects
SARS-CoV-2 ,COVID-19 ,vaccine ,vaccinia virus ,spike protein ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines provide essential tools for the control of the COVID-19 pandemic. A number of technologies have been employed to develop SARS-CoV-2 vaccines, including the inactivated SARS-CoV-2 particles, mRNA to express viral spike protein, recombinant spike proteins, and viral vectors. Here, we report the use of the vaccinia virus Tiantan strain as a vector to express the SARS-CoV-2 spike protein. When it was used to inoculate mice, robust SARS-CoV-2 spike protein-specific antibody response and T-cell response were detected. Sera from the vaccinated mice showed strong neutralizing activity against the ancestral Wuhan SARS-CoV-2, the variants of concern (VOCs) B.1.351, B.1.617.2, and the emerging B.1.1.529 (omicron). This finding supports the possibility of developing a new type of SARS-CoV-2 vaccine using the vaccinia virus vector.
- Published
- 2022
- Full Text
- View/download PDF